Thermo Fisher Scientific Ion Torrent Oncomine Myeloid Assay GX v2
Thermo Fisher Scientific has released the Ion Torrent Oncomine Myeloid Assay GX v2, a next-generation sequencing assay that allows researchers to gather comprehensive mutational results from myeloid samples in a single day using the company's Ion Torrent Genexus System.
The Oncomine Myeloid Assay GX v2 offers a comprehensive panel to profile key biomarkers for all major myeloid disorders. It's optimized to detect a wide range of variants, including challenging-to-sequence targets such as FLT3-ITD, CALR, and CEBPA, Thermo Fisher said. The updates for this version of the assay include additional DNA and RNA targets, improved sequencing of key GC-rich regions, and the ability to run the RNA and DNA panels separately.
The assay also features an automated workflow, enabling samples to be processed from specimen to report with only 20 minutes of hands-on time for technicians and minimal user intervention; an expanded panel with simultaneous profiling of 45 genes and 30 fusion drivers covering more than 700 unique fusions; full specimen coverage, including whole blood, peripheral blood lymphocytes, and bone marrow; and integrated reporting, with annotated variant reports and the latest relevant evidence from public data sources.
Personalis NeXT Personal
Personalis has launched NeXT Personal, a tumor-informed liquid biopsy assay designed to detect and quantify molecular residual disease and recurrence in patients previously diagnosed with cancer. The assay boasts sensitivity down to the 1 part-per-million range and uses whole-genome sequencing of a patient's tumor to identify up to 1,800 somatic variants that are subsequently used to create a personalized liquid biopsy panel for each patient.
With broader content than other available assays, these panels can also be used to detect clinically relevant alterations with a potential impact on therapeutic decision-making. Personalis said NeXT Personal is currently for research use only and that it plans to release it as a clinical test next year.
Menarini Silicon Biosystems DEPArray PLUS Application
Menarini Silicon Biosystems has launched its FFPE Rescue Application to enable molecular testing on formalin-fixed, paraffin-embedded samples with low tumor cell contents. Enabled by the sorting capabilities of the company's DEPArray PLUS instrument, the application can be used to isolate a sufficient number of tumor cells to generate relevant molecular data, even from FFPE tissues that were previously discarded from conventional next-generation sequencing processing, the company said. As such, the workflow can reduce the failure rates of FFPE molecular analyses and provide clinical researchers with valuable information about actionable mutations, potentially improving clinical trial recruitment and allowing more patients to access new targeted therapies, the company added.
For more new products and services, please visit the New Products page on our website.